Lymphedema

Background

Lymphedema is common globally; contemporary estimates vary and are method-dependent.

Primary Lymphedema

• Congenital or genetic defects in lymphatic development.
• Milroy disease: congenital, VEGFR3 mutation.
• Meige disease: onset around puberty.
• Late-onset primary lymphedema (20–40 yrs).

Secondary Lymphedema

• Cancer-related: most common cause in developed countries.
• Breast cancer (axillary lymph node dissection, radiation).
• Gynecologic malignancies (pelvic node dissection).
• Prostate and urologic cancers.
• Infectious:
• Filariasis (Wuchereria bancrofti) – leading global cause.
• Other:
• Trauma, chronic venous disease (see 13CVI), obesity, inflammatory conditions.

Pathophysiology

• Lymphatic transport failure → accumulation of protein-rich interstitial fluid.
• Chronic inflammation → fibroblast activation, adipose deposition, fibrosis.
• Progressive skin changes: hyperkeratosis, papillomatosis, lymphorrhea.
• Immunologic dysfunction: impaired dendritic/T-cell trafficking → recurrent cellulitis.

Stages (ISL classification)

• Stage 0: latent/subclinical.
• Stage I: pitting edema, reversible with elevation.
• Stage II: persistent swelling, fibrosis.
• Stage III: elephantiasis, skin thickening, recurrent infections.

Clinical Presentation

• Chronic, insidious swelling (usually limbs).
• Heaviness, tightness, decreased ROM.
• Pitting early, non-pitting later.
• Stemmer’s sign: inability to pinch skin at base of second toe/finger.
• Recurrent cellulitis/erysipelas.
• In advanced cases: elephantiasis, verrucous skin changes, ulcers.

Clinical

• History of surgery, radiation, infection.
• Staging by ISL criteria.

Imaging

Computed tomography (CT) has a limited role in lymphedema characterization but may help exclude alternative diagnoses such as 12VTE. The characteristic honeycomb appearance of lymphedematous tissue is more consistently demonstrated on MRI.

Conservative (cornerstone)

Complete decongestive therapy (CDT) remains first-line treatment, consisting of an intensive decongestive phase (short-stretch multilayer bandaging, manual lymphatic drainage, exercise, and skin care) followed by lifelong maintenance with appropriately fitted compression garments. ^{[1] [2]}

• Compression: Transition from bandaging to flat-knit garments. Typical compression targets are 20–30 mmHg for the upper limb and 30–40+ mmHg for the lower limb as tolerated. Treatment should be individualized based on disease stage, patient tolerance, and comorbidities.
• Exercise: Supervised, progressive resistance and aerobic activity are safe and recommended with compression in place.
• Infection prevention: Meticulous skin care is essential. Prophylactic penicillin V should be considered for patients with recurrent cellulitis.
• Pharmacologic agents: No disease-modifying therapy is currently approved. Anti-inflammatory strategies (e.g., ketoprofen) have early-phase data but are not standard of care.
• Adjuncts: Intermittent pneumatic compression may be considered for selected patients as an adjunct to CDT. Weight management, skin care, and prompt treatment of cellulitis are emphasized. Antibiotic prophylaxis should be considered for patients with recurrent episodes.

^{[1] [3] [4]}

Surgical and Interventional

1. Physiologic microsurgery

• Lymphaticovenular anastomosis (LVA): Best suited for earlier, fluid-predominant disease. This technique aims to bypass obstructed lymphatics by creating anastomoses into venules.
• Vascularized lymph node transfer (VLNT): Considered for selected patients with recurrent infections or failure of complete decongestive therapy, often combined with ongoing compression therapy.
• The evidence base demonstrates volume reduction and decreased infection frequency, though heterogeneity in surgical techniques and outcome measures persists.

^{[5] [6] [1]}

2. Reductive surgery

• Liposuction with continuous postoperative compression is effective for advanced fibroadipose enlargement. The Charles procedure (excisional debulking) is reserved for exceptional cases.

^{[7] [1]}

3. Image-guided lymphatic interventions

• Lymphatic embolization is established for treatment of lymphatic leaks (e.g., chylothorax) but is not indicated for extremity lymphedema. Lymphangioplasty for peripheral lymphedema remains investigational with limited supporting evidence.

^[1]

4. Medical therapy

• No pharmacologic cure is currently approved. Early-phase clinical data support anti-inflammatory modulation (e.g., ketoprofen), but routine use is not yet recommended.

^{[4] [1]}

Follow-up

• Lifelong compression and CDT adherence.
• Imaging surveillance after microsurgical reconstruction.
• Prompt antibiotics for cellulitis.
• Patient education critical for compliance.

Guidelines

Rockson SG, et al. Pilot study of ketoprofen in lymphedema. JCI Insight. 2018. PubMed. ^[4]

Risk stratification and incidence of cancer-related lymphedema

Breast cancer-related lymphedema (BCRL) incidence varies by axillary management and radiation exposure. Risk is higher after axillary lymph node dissection (ALND) compared to sentinel node biopsy. Obesity and infection further increase risk. Prospective surveillance programs and early compression therapy are recommended for high-risk patients. ^{[8] [1]}

Differential diagnosis and objective limb measurement

The differential diagnosis includes lipedema, phlebolymphedema, 12deep venous thrombosis with venous insufficiency (see 13CVI), and myxedema. Standard objective measurement methods include tape-derived truncated cone volume calculation, perometry, and water displacement volumetry. Diagnostic thresholds are typically defined as a ≥10% volume difference or ≥2 cm circumference difference between limbs, and these measurements are used to track treatment response. ^[1]

Antibiotic prophylaxis for recurrent cellulitis in lymphedema

Prophylactic penicillin V should be considered for patients experiencing two or more cellulitis episodes per year. The decision should involve shared decision-making with the patient and requires periodic re-evaluation of ongoing need. ^{[3] [1]}

Patient selection and expectations for lymphatic surgery

Surgical intervention is guided by International Society of Lymphology (ISL) staging and indocyanine green (ICG) lymphography patterns. Lymphaticovenular anastomosis (LVA) is best suited for earlier, fluid-predominant disease. Vascularized lymph node transfer (VLNT) is considered for selected patients who have failed complete decongestive therapy or experience recurrent infections. Liposuction is effective for advanced fibroadipose enlargement. All surgical interventions require ongoing compression therapy. Outcomes remain heterogeneous due to variation in surgical techniques, patient selection, and outcome measures, highlighting the need for standardized outcome reporting. ^{[5] [1]}